

## Seeking Innovative Therapies for the Treatment of Skin Disorders

Almirall is a global biopharmaceutical company focused on skin health based in Barcelona. They collaborate with scientists and healthcare professionals to address patient's needs and make a difference in their lives. They invest in differentiated and ground breaking **medical dermatology** products to bring their innovative solutions to patients in need. **Almirall is seeking partnering opportunities on new assets in preclinical or clinical development stages that could be useful for the treatment of dermatological diseases.**



### Approaches of Interest

These proposed new assets should:

- **Target immuno-inflammatory pathways with rationale for dermatological indications** such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo
- Or be **suitable for non-melanoma skin cancer** (basal and squamous cell carcinoma, and cutaneous T cell lymphoma), or **rare dermatological indications** (e.g., epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid)
- **Involve any therapeutic modality** such as small molecules, biologics, mRNA therapeutics or gene therapy approaches

### Out of Scope

- Reformulations or drug delivery systems
- Therapeutic approaches to treat melanoma
- Natural products, aesthetic or cosmetics products

### Developmental Stages of Interest

- Almirall are interested in opportunities from preclinical to clinical stages up to Phase II clinical trials
- For preclinical assets, compelling *in vitro* and *in vivo* evidence of efficacy will be highly valuable

### Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Almirall is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and partnership opportunities.

### Opportunities sought

- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies
- Technologies

### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **15th August 2022 - 10:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

